Tenax Therapeutics is trading 6.47% down now at $2.17, with no fresh company announcement or clearly documented negative catalyst identified for August 26.
- It gained 25.41% to $2.32 on August 25.
- Recent coverage centered on Adar1 Capital Management’s approximately $1.81 million purchase of 1,025,867 shares, supporting the prior rally.
- The broader biotech sector is up 2.06%, so sector weakness does not explain the move.